Pre-clinical study data of Stemline Therapeutics' IL-3R targeting agents to be presented at the ASH meeting

Stemline Therapeutics, Inc. today announced that data from pre-clinical studies of its IL-3R targeting agents, SL-401 and SL-501, in both in vitro and animal models of human chronic myeloid leukemia (CML) have been selected for poster presentation at the upcoming 51st Annual Meeting of the American Society of Hematology (ASH), to be held in New Orleans from December 5-8, 2009. The poster will be presented by Stemline's collaborators at The University of Texas M.D. Anderson Cancer Center.

The data demonstrate in vitro and in vivo activity of both SL-401 and SL-501 against CML and CML cancer stem cells as single agents, and in combination with tyrosine kinase inhibitors (TKIs). Results also include activity of these IL-3R targeting agents against CML cells with mutations that render them resistant to TKIs.

Details on the abstract selected for presentation are as follows:

Abstract #: 2172 TITLE: Targeting IL-3 Receptor in Chronic Myeloid Leukemia Lead Author Olga Frolova, MD, PhD Session Name Chronic Myeloid Leukemia -Biology and Pathophysiology excluding Therapy Poster I Date Sunday, December 6, 2009 Presentation Time: 6:00PM - 8:00PM Location: Hall E (Ernest N. Morial Convention Center) Poster Board no.: II-149

A copy of the above referenced abstract can be viewed online through the ASH website (www.hematology.org).

SOURCE Stemline Therapeutics, Inc.